Results 261 to 270 of about 47,580 (341)

Integrated Imaging Probe and Bispecific Antibody Development Enables In Vivo Targeting of Glypican-3–Expressing Hepatocellular Carcinoma [PDF]

Peiman Habibollahi, Alexey Gurevich, James Z. Hui, Kelley Weinfurtner, George McClung, J Adler, Michael C. Soulen, David E. Kaplan, G. Nadolski, Stephen J. Hunt, Andrew Tsourkas, T. Gade   +11 more
openalex   +1 more source

Targeting neutrophil‐driven immunosuppression: A strategy to overcome immune checkpoint inhibitor resistance

Clinical and Translational Medicine, Volume 16, Issue 1, January 2026.
TANs drive ICI resistance via antitumour immune remodelling, angiogenesis promotion, and elevation of tumour mutation burden Neutrophil biomarkers (e.g., NLR, TAN abundance) show strong predictive value for ICI response and prognosis. Targeting TAN recruitment, polarization, function and NETosis represents a promising strategy to overcome ICI ...
Ying Ning, Ke Lei, Xinyan Gao, Yan Kong, Yuping Shan, Tian Tian, Zhumei Cui, He Ren   +7 more
wiley   +1 more source

Successful Treatment of Diffuse Large B-Cell Lymphoma and Antisynthetase Syndrome with Bispecific Antibody Glofitamab. [PDF]

Cancer Manag Res
Wei C, Zhang M, Zhao D, Zhang W, Zhang Y.   +4 more
europepmc   +1 more source

Developing and Characterizing the Tumor-TargetingEfficiency of an Anti-EphA2-CD11b Bispecific Antibody

Peggy A. Birikorang (21437647), Dominic M. Menendez (18227459), Robert Edinger (17354106), Gary Kohanbash (4709257), W. Barry Edwards (437663)   +4 more
openalex   +1 more source

Figure S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy [PDF]

Amr El Zawily, Frederick S. Vizeacoumar, Renuka Dahiya, Sara L. Banerjee, Kalpana K. Bhanumathy, Hussain Elhasasna, Glinton Hanover, Jessica C. Sharpe, Malkon G. Sanchez, Paul Greidanus, R. Greg Stacey, Kyung‐Mee Moon, Ilya Alexandrov, Juha P. Himanen, Dimitar B. Nikolov, Humphrey Fonge, Aaron P. White, Leonard J. Foster, Bingcheng Wang, Behzad M. Toosi, Nicolas Bisson, Tajib A. Mirzabekov, Franco J. Vizeacoumar, Andrew Freywald   +23 more
openalex   +1 more source

Synthetic lethality in cancer therapy: Mechanisms, models and clinical translation for overcoming therapeutic resistance

Clinical and Translational Medicine, Volume 16, Issue 1, January 2026.
Application of synthetic lethality screening in drug resistance models. Abstract Background and Rationale Synthetic lethality (SL)‐based strategies hold significant promise for overcoming therapeutic resistance, a critical bottleneck in cancer treatment where cancer cells evade anticancer therapies, leading to diminished efficacy or treatment failure ...
Junyan Li, Liyuan Zhang, Yan Shang, Juan Liu, Hailong Zhao   +4 more
wiley   +1 more source

Novel tetravalent bispecific antibody, PSMA/TRAIL‑R2 REGULGENT™, induces selective tumor cell apoptosis without hepatotoxicity. [PDF]

Oncol Rep
Nakayama M, Takagi-Maeda S, Machino Y, Nihira K, Inoue M, Takahashi N, Usami K.   +6 more
europepmc   +1 more source

Navigating the evolving management of smoldering multiple myeloma

HemaSphere, Volume 10, Issue 1, January 2026.
Abstract Smoldering multiple myeloma (SMM) represents an intermediate clinical stage between monoclonal gammopathy of undetermined significance (MGUS) and symptomatic multiple myeloma (MM). SMM carries a highly variable risk of progression to MM, requiring individualized risk stratification to guide management.
M. Bakri Hammami, Rafael R. Canevarolo, Ariosto S. Silva, Melissa Alsina, Nagi Kumar, Rachid Baz, Kenneth H. Shain   +6 more
wiley   +1 more source

A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancer. [PDF]

Cancer Chemother Pharmacol
Hudson A, Jayaram A, Garmezy B, Zorko NA, Zarrabi KK, Mathews L, Rupnow B, Li M, Ghosh D, Urtishak K, Francis P, Wang SC, Attiyeh E, de Bono J.   +13 more
europepmc   +1 more source

NK cell depletion in bispecific antibody therapy is associated with lack of HIV control after ART interruption [PDF]

Nerea Sánchez-Gaona, David Perea, Adrián Curran, Joaquín Burgos, Jordi Navarro, Paula Suanzes, Vicenç Falcó, Enrique Martín‐Gayo, Meritxell Genescà, Jorge Carrillo, María J. Buzón   +10 more
openalex   +1 more source